(Reuters) – Swiss drugmaker Actelion‘s 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday.
Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement.
Sales rose 18 percent to 2.42 billion francs, in line with the 2.41 billion francs expected in a Reuters poll.
Get the full story at our sister site, Drug Delivery Business News.
The post Actelion reports income, revenue growth in FY2016 appeared first on MassDevice.